The State of the Art in Chronic Prurigo Nodularis Authors: Esther Serra-Baldrich, Ángeles Flórez, Marc Julià Manresa, Francisco Javier Ortiz de Frutos, José-Juan Pereyra-Rodriguez, Bibiana Pérez, Ignasi Figueras Published: 2026 ABSTRACT AbstractChronic prurigo nodularis (CPN) is a highly burdensome chronic inflammatory dermatosis characterized by intensely pruritic papulonodular lesions that may persist for years. Its pathophysiology reflects a neuro–immune–fibrotic axis in which type-2 cytokines (IL-4/IL-13/IL-31), neuropeptides, and profibrotic signaling interact to sustain the itch–scratch cycle and dermal fibrosis. CPN predominantly affects older adult women and is frequently associated with dermatologic, neuropsychiatric, and cardiometabolic comorbidities. Definition, nomenclature, and management remain areas of debate, with relevant differences between European and US consensus documents. The therapeutic landscape has expanded with dupilumab and nemolizumab, the only agents currently supported by phase III evidence, whereas JAK inhibitors remain promising but investigational options that require careful safety contextualization. This narrative review synthesizes current knowledge on CPN, from definition and epidemiology to etiopathogenesis and evolving therapy, while highlighting persistent unmet needs in diagnosis and management.Keywords: Fibrosis, Immune dysregulation, Neural dysregulation, Prurigo, Pruritus, Quality of life Key Summary Points Chronic prurigo nodularis (CPN) is a debilitating inflammatory skin disease defined by intense, chronic itch and nodular lesions that significantly impair a patient’s quality of life and psychological well-being.The disease is driven by a self-perpetuating “itch–scratch cycle” involving a complex neuro–immune–fibrotic axis where type-2 cytokines (IL-4, IL-13, and IL-31) and neuropeptides promote persistent inflammation and skin fibrosis.CPN is a highly heterogeneous condition frequently associated with a broad range of comorbidities, including atopic dermatitis, chronic kidney disease, diabetes, and psychiatric disorders such as anxiety and depression.The therapeutic landscape is currently shifting from empirical, off-label treatments toward targeted biologics, with dupilumab and nemolizumab being the only agents currently supported by high-level phase III clinical evidence.There remains a critical need for standardized clinical guidelines and personalized “treat-to-target” strategies to address existing gaps in managing special populations and the neurogenic components of the disease. Introduction Chronic prurigo nodularis (CPN), referred to as prurigo nodularis (PN) in much of US literature, is a chronic inflammatory skin disease characterized by intensely pruritic papulonodular lesions that may persist for years or even decades [1–9]. Patients experience not only intractable itch but also pain, stinging, burning, and tingling, which promotes repeated scratching, scarring, and a substantial disease burden. Moderate-to-severe disease can impair quality of life to a degree comparable with other chronic disorders such as hypertension or arthritis [10]. This burden is further amplified by frequent comorbidities, including atopic dermatitis, diabetes, chronic kidney disease, and psychiatric disorders, which contribute to the marked heterogeneity of CPN [11]. Despite the diversity of associated conditions, all cases of CPN share a common pathophysiologic mechanism known as “the itch–scratch cycle”, in which uncontrollable itch leads to persistent scratching and the subsequent development of the nodular cutaneous lesions [12, 13]. Recent molecular and histopathological studies highlight the role of a neuro–immune–fibrotic axis in which type-2 cytokines (IL-4/IL-13/IL-31), neuropeptides, and profibrotic pathways drive the itch–scratch cycle, epidermal acanthosis, and fibrosis [14]. Currently, there is no universally accepted definition of CPN and no standardized clinical guidelines for its management. Existing expert consensus documents propose largely empirical therapeutic strategies, with limited guidance on treatment sequencing, combinations, optimal duration, or management of special populations [1, 15]. One of the major unmet needs in CPN care is the development of clear therapeutic algorithms. Recent advances, particularly the approval of dupilumab and nemolizumab [16, 17], the only agents supported by phase III evidence, together with emerging JAK inhibitors, are reshaping the treatment landscape. This narrative review synthesizes current knowledge on CPN, including its definition, epidemiology, etiopathogenesis, and clinical impact. It also integrates evidence from clinical trials and real-world studies to support clinicians in the diagnosis, assessment, and management of this challenging condition. Methods We performed a targeted literature search in MEDLINE (PubMed), Embase, and the Cochrane Library from January 2015 to September 2025. The strategy combined MeSH/Emtree terms and free-text keywords related to CPN/PN, epidemiology, pathophysiology (including IL-4, IL-13, IL-31, neuroimmune pathways, and fibrosis), diagnosis, patient-reported outcomes, and treatments (dupilumab, nemolizumab, JAK inhibitors). Search terms also covered emerging biologics and their targets (e.g., vixarelimab/OSMRβ, barzolvolimab/CDX-0159/KIT, rocatinlimab/OX40, stapokibart/CM310/IL-4Rα, SHR-1819/IL-4Rα), alongside class terms (e.g., oncostatin-M/OSM, IL-4 receptor, OX40 antagonists, KIT inhibitors). We included human studies in English or Spanish that addressed CPN definition or classification, epidemiology, comorbidities, pathophysiology, diagnosis, outcome measures, or treatment. We prioritized clinical practice guidelines, systematic reviews or meta-analyses, randomized and prospective interventional studies, large observational cohorts, and selected seminal mechanistic studies. We excluded reports centered on other chronic pruritic disorders without extractable CPN data, nonprimary literature not relevant to the objectives, and isolated case reports except when they illustrated an emerging therapy with no higher-level evidence. Reference lists of key reviews and guidelines were hand-searched to identify additional records. The final narrative synthesis included 127 references. Because this review was conceived as a narrative review rather than a systematic review, a Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)-style screening flow, formal risk-of-bias assessment, and a prospectively recorded record-level denominator for all screened citations were not available; this limitation is now stated explicitly to avoid overstating methodological rigor. However, we describe the search process to enhance transparency and adhere to the principles of the Scale for the Assessment of Narrative Review Articles (SANRA) [18]. Relevant Aspects of Chronic Prurigo Nodularis Definition Although dermatologists generally share a clear clinical understanding of what CPN is, its nomenclature has historically been a source of confusion. In the USA, the term prurigo nodularis (PN) is preferred and is used to encompass all chronic prurigo variants, as it is considered sufficiently descriptive (ICD-10: L28.1) [15]. In contrast, in Europe, chronic prurigo is employed as the umbrella term, with CPN designated as its nodular subtype [1, 2]. Chronic prurigo is therefore used as a broad category that includes several clinical morphologies, such as papular, nodular, plaque, or umbilicated types of the same disease. The term chronic prurigo was used in literature prior to the establishment of the European Academy of Dermatology and Venereology Task Force in 2018 with the purpose of reaching expert consensus on the definition and classification of prurigo associated terms [1]. Epidemiology Data on the incidence and prevalence of CPN remain scarce and heterogeneous, partly because the disease is underrecognized, and case ascertainment differs across datasets [19]. Reported prevalence ranges from 9 to 210 per 100,000 in Europe and the USA [8]. In large European and US cross-sectional studies, older adults predominate, with mean ages of 64 and 56 years, respectively, although cases also occur in other age groups, including children [10, 20–22]. No consistent sex association has been demonstrated, with rates similar to the general population or only slightly higher in women in some cohorts [8, 10, 20, 22, 23]. In England, epidemiological data indicate an increase in CPN prevalence from 2.49 per 10,000 inhabitants in 2007 to 8.8 per 10,000 inhabitants in 2019 [24]. These findings differ from those of Morgan et al., who reported a prevalence of 3.27 per 10,000 inhabitants in 2018 and an incidence of 2.88 per 100,000 inhabitant-years between 2008 and 2018 [25]. However, these studies used markedly different methodologies [25, 26]. Etiopathogenesis The etiology of CPN remains unclear in most reports. The disease frequently occurs in association with dermatologic, systemic, neurologic, or psychiatric disorders, although it can also appear without an identifiable underlying condition [1, 6, 22]. Ortiz de Frutos et al. classified CPN according to etiological factors and comorbidities into four groups: (1) dermatological disease-related CPN, most commonly linked to atopic dermatitis and less often to psoriasis, lichen planus, or hypertrophic lupus; (2) systemic/metabolic disease-related CPN, including diabetes mellitus, chronic kidney disease, hematologic and hepatobiliary disease, and drug-induced pruritus; (3) psychiatric disease-related CPN, associated with obsessive–compulsive, impulse control, or anxiety–depressive disorders; or (4) idiopathic CPN, defined as CPN without an associated disease, representing a very small proportion of cases [27]. These diverse comorbid profiles contribute to marked clinical heterogeneity. Etiology and comorbidities are often intertwined, and it is frequently unclear whether one condition precedes or results from the other or how CPN and comorbidities mutually influence each other [28]. Despite these differences, patients share a common pathophysiologic mechanism: the itch–scratch cycle, maintained by a complex interplay of immunologic, environmental, and disease-related factors (Fig. 1) [1, 6, 22]. Advances in molecular and histopathologic research have substantially improved our understanding of CPN, which is now considered a multifactorial disorder driven by immune dysregulation, neuronal sensitization, and—unlike most other chronic pruritic diseases—a prominent profibrotic response [14]. Neuro–immune–fibrotic axis sustaining the itch–scratch cycle in chronic prurigo nodularis. CGRP calcitonin gene-related peptide, IL interleukin, ILC2 type 2 innate lymphoid cells, TSLP thymic stromal lymphopoietin, VIP vasoactive intestinal peptide Immune Dysregulation Changes in the skin of patients with CPN perpetuate the itch–scratch cycle, causing chronic nonhistaminergic pruritus and persistent inflammation [12, 29–31]. When the epithelium is damaged—by scratching or by proinflammatory cytokines and pruritogenic mediators—keratinocytes release itch-inducing mediators (thymic stromal lymphopoietin, IL-33, cathepsin S, kallikreins) that activate sensory neurons [12, 29]. Additional pruritogenic and type-2 cytokines from eosinophils, basophils, type-2 innate lymphoid cells, Th2 lymphocytes, and mast cells (IL-4, IL-13, IL-31, histamine, tryptase) further stimulate these neurons and contribute to producing itching (Fig. 1) [12, 32–34]. Within this microenvironment, eosinophils and mast cells are particularly relevant. Eosinophils release neuropeptides, eosinophil cationic protein (ECP), eosinophil-derived neurotoxin (EDN), eosinophil protein X (EPX), and major basic protein; ECP and EDN, which are neurotoxic, are markedly elevated in CPN skin [35]. Mast cells are an important source of oncostatin M and show high IL-31RA expression in CPN, and mast cell–associated mediators and receptors (IL-4, IL-13, IL-31, MRGPRX2, PAR2) also contribute to disease pathogenesis [36]. Type-2 inflammation is central in CPN. IL-4, IL-13, and IL-31 directly activate sensory neurons via their receptors (Fig. 1) [37, 38]. IL-4 and IL-13 signaling through IL-4Rα sensitizes neurons to subthreshold levels of other pruritogens, including IL-31, a key pruritogen in CPN [12, 38–42]. Moreover, type-2 cytokines participate in feedback loops, as IL-4 induces IL-31 expression and release by Th2 cells, further amplifying pruritus and inflammation [38]. Neural Dysregulation CPN is also characterized by structural and functional alterations of cutaneous nerves. In the epidermis, intraepidermal nerve fiber density is reduced but returns to normal after lesion resolution; nerve growth factor (NGF) receptor–immunoreactive fibers and protein gene product (PGP)-9.5+ fibers are likewise decreased [35, 43]. In the dermis, however, neuronal hyperplasia is observed, with PGP-9.5 and NGF receptor staining showing significantly denser immunoreactive structures than in healthy controls [35, 43, 44]. Chronic activation of sensory neurons—by scratching or pruritogenic mediators—induces neurogenic inflammation and peripheral sensitization [29, 30]. Activated neurons release neuropeptides (calcitonin gene-related peptide, substance P, vasoactive intestinal polypeptide) that stimulate immune cells to produce IL-4, IL-13, and other mediators, which in turn further activate neurons, creating a self-reinforcing loop. These signals are transmitted to the central nervous system, eliciting itch and perpetuating the itch–scratch cycle (Fig. 1) [45]. Fibrotic Response Cutaneous fibrosis is a defining histopathological feature of CPN [9, 46]. It arises from repeated tissue injury and represents a reparative response to stimuli such as scratching [47]. Pruritus-related mediators, including neuropeptides and histamine, also promote dermal inflammation and fibrosis (Fig. 1) [46]. However, type-2 cytokines are the main fibrotic drivers: IL-4 and IL-13, essential for normal wound healing, become pathogenic when dysregulated, activating profibrotic pathways that induce excessive fibroblast proliferation and extracellular matrix deposition [47, 48]. Fibroblasts in CPN display a WNT5A+ phenotype, are apoptosis-resistant, and enhance dermal fibrosis and type-2 inflammation via periostin release [49, 50]. IL-31 further activates IL-31RA on fibroblasts, altering genes involved in proliferation and collagen synthesis, thereby contributing to fibrosis [51]. CPN is also characterized by a hyperkeratotic epidermis with irregular epidermal hyperplasia, focal parakeratosis, papillary dermal fibrosis, and inflammatory infiltration [52]. IL-22, produced in type-3 (Th17/Th22) responses, is a key proinflammatory cytokine driving these epidermal changes. It promotes keratinocyte proliferation, fuels skin inflammation, and modulates wound healing and epidermal differentiation, with elevated levels detected in both skin and serum of patients with CPN [52, 53]. Comorbidities A systematic review identified diseases related to CPN and grouped them into: (1) pruritic diseases that may lead to or coexist with CPN, (2) inflammatory diseases, and (3) age-related diseases, more frequent in older adults, in whom CPN is also more common [11]. Studies from several countries similarly show that many conditions are more prevalent in CPN, notably, atopic dermatitis, asthma, diabetes, hyperlipoproteinemia, heart failure, hypertension, chronic obstructive pulmonary disease, and chronic kidney disease [11, 27, 28, 54–56]. Up to 50% of patients with CPN have a history of atopy, and the term “atopic dermatitis with a prurigo phenotype” is often used, although the temporal relationship between dermatitis and prurigo is unclear [11]. Single-cell RNA sequencing has shown molecular differences: oligoclonal cytotoxic T cells are present in atopic dermatitis but not in CPN, and type 2 myeloid responses are stronger in atopic dermatitis, whereas CPN is dominated by a stromal response (fibrosis, angiogenesis, collagen remodeling, neurogenesis) [57]. Among systemic comorbidities, chronic kidney disease is particularly relevant. Although many patients with chronic kidney disease and pruritus do not develop prurigo, chronic kidney disease–associated pruritus and CPN share dermatologic, neuropathic, and immune dysregulation features [58]. Renin–angiotensin system dysregulation may also contribute to both CPN lesions and kidney disease [59, 60]. Other systemic associations include infectious, endocrinologic, cardiovascular, and neoplastic diseases such as lymphoma, likely linked to inflammatory imbalance, neural dysregulation, or a profibrotic tendency. In hepatic disease, Marani et al. found that patients with CPN (versus atopic dermatitis) showed gene signatures associated with liver disease, liver fibrosis, and chronic hepatitis [61]. The most prevalent metabolic comorbidities are type 2 diabetes (≈ 35%) and chronic liver disease (≈ 16%), both capable of causing peripheral neuropathy and supporting a role for neural dysregulation in CPN pathogenesis [20, 62]. Psychiatric comorbidities, especially anxiety (45.6%) and depression (16.4%), are also common [7, 63]. Sleep disturbance is frequent and associated with elevated C-reactive protein levels, which in turn increase cardiovascular risk [64]. In one analysis, patients with CPN were clustered into: class 1, atopy (high atopic burden, no psychiatric or cardiovascular disease, lower mean age 38.7 years); class 2, neuropsychiatric (high neuropsychiatric burden, 68.9% women); class 3, high comorbidity burden (multiple chronic pruritic, neuropsychiatric, cardiopulmonary, and atopic diseases); and class 4, chronic and cardiopulmonary diseases [65]. This stratification may aid clinical and therapeutic decision-making. In a multicenter study of 513 patients with CPN with various comorbidities, itch intensity (worst itch intensity in the previous 24 h, worst itch numeric rating scale [WI-NRS]) was significantly associated only with hypertension—hypertensive patients reported more intense pruritus—whereas quality of life (Five-Item Life Quality Questionnaire, 5-PLQ) was significantly worse in those with concomitant depression [66]. Impact on Patients Patients with CPN experience a multidimensional burden, affecting both physical and psychological health [10]. Beyond intense itch and papulonodular lesions with excoriations and scarring [1, 10, 13, 22], they frequently report pain and somatosensory symptoms such as stinging, burning, tingling, and heat/cold dysesthesia [13, 22]. Compared with other chronic conditions with pruritus, the itching experienced by patients with CPN is among the most severe, with an intensity of 7 out of 10 [7, 10, 22]. More than 53% report skin pain (skin pain-numeric rating scale (NRS) ≥ 3), and more than 54% report burning, stinging, or tingling (burning/stinging/tingling-NRS ≥ 3) [7]. Although nodules may gradually resolve, they often leave scarring and hyper- or depigmentation, especially if undertreated, adding considerable psychoaffective distress [67, 68]. This burden leads to marked impairment in quality of life, comparable to other pruritic dermatoses (notably contact dermatitis and lichen planus) and systemic diseases such as hypertension, stroke, coronary artery disease, and arthritis, through sleep disturbance, absenteeism, and disruption of daily activities, particularly in those with higher itch scores [1, 7, 10, 69–74]. Emotional well-being is also affected, with frequent anxiety, depression, anger, disgust, shame, and helplessness and increased use of antidepressants and anxiolytics [1, 7, 75]. Patients with CPN show higher odds than those with atopic dermatitis of behavioral and eating disorders, attention-deficit/hyperactivity disorder, substance abuse, schizophrenia, and self-harm [19]. A systematic review and meta-analysis found that they are 1.3-, 1.9-, and 2-fold more likely to experience depression, anxiety, and suicidal ideation/self-harm, respectively, than healthy controls, although causality remains unclear [76]. The overall burden is further amplified by comorbidities [3, 10, 15, 19, 22]. A higher Charlson Comorbidity Index in CPN (1.53) compared with atopic dermatitis (0.53) and psoriasis (1.16) is associated with greater use of specialist healthcare services [77]. Diagnosis and Evaluation of Chronic Prurigo Nodularis CPN includes several lesion types, with papulonodular lesions being the most common [8]. Different prurigo lesions may coexist, and no subtype lesion necessarily reflects a more advanced or chronic stage [5, 6, 23]. Papulonodular lesions can range from a few to hundreds, typically distributed bilaterally and symmetrically on the extensor surfaces of the arms and legs [5, 6, 8, 78]. The “butterfly sign” may be observed, with sparing of areas inaccessible to scratching, classically the mid-back [6, 23]. Ulcerations may also occur, irrespective of CPN subtype [79]. There is no consensus on whether CPN is a distinct disease or a consequence of other conditions; therefore, current guidelines seek to harmonize diagnostic criteria. European and American documents diagnose CPN clinically using three main signs or symptoms, summarized in Table 1. Both require chronic pruritus lasting at least 6 weeks [1, 2, 15, 80]. The European guideline additionally emphasizes multiple localized or generalized pruritic lesions and a history or signs of repeated scratching, whereas the American consensus highlights nodular lesions plus repeated scratching, pinching, or rubbing [1, 15, 80]. Terminology also differs: “chronic nodular prurigo” in Europe versus “prurigo nodularis” in the USA (Table 1). Differential diagnosis remains essential, and Table 2 highlights the main alternatives and distinguishing features [2, 3, 15, 81–83]. Table 1Clinical diagnosis of chronic prurigo nodularisEuropean guidelinesAmerican guidelinesChronic nodular prurigoPrurigo nodularisChronic pruritus lasting 6 or more weeks Localized or widespread presence of multiple pruritic lesions*Nodular lesions History and/or signs of repeated scratching (e.g., excoriations and scars)History and/or signs of repeated scratching, pinching, or rubbing*Pruriginous lesions are defined as being “excoriated, scaling and/or crusted papules and/or nodules and/or plaques, often with a whitish or pink center and hyperpigmented border” Clinical diagnosis of chronic prurigo nodularis *Pruriginous lesions are defined as being “excoriated, scaling and/or crusted papules and/or nodules and/or plaques, often with a whitish or pink center and hyperpigmented border” Table 2Differential diagnosis of chronic prurigo nodularisDiseaseDifferential characteristicsPerforating dermatosesHematoxylin–eosin skin biopsy or special stains can confirm collagen perforation, immune infiltration, and secondary infection singsNodular pemphigoidIt is often characterized by larger plaques, often with large areas of central erosion, ulceration, and/or blisters. Biopsy shows evidence of subepidermal clefting, and direct immunofluorescence shows linear deposition of IgG and C3 along the basement membraneActinic prurigoAcute eruptions of severe pruritic papules or nodules, often accompanied by cheilitis and conjunctivitis. It presents with extreme photosensitivity to ultraviolet A and ultraviolet B raysEpidermolysis bullosaMultiple variants (e.g., prurigo-like epidermolysis bullosa and acquired epidermolysis bullosa) that may present with nodular lichenified lesions similar to prurigo. Immunofluorescence shows antibodies against type VII collagen in the dense sublaminaHypertrophic lichen planusHyperkeratotic plaques and nodules that most commonly affect the shins and ankles. Histopathology may be very similar to prurigo nodularis, but there is often lichenoid inflammation, unlike prurigo nodularisNeurotic excoriations/skin-picking disorderA psychiatric condition characterized by excessive skin picking; it can lead to excoriations with slightly raised areas that resemble prurigo nodularis lesions. Psychiatric evaluation can aid in identificationScabies/fungal infectionsIt can be distinguished on the basis of skin scraping findings and mycological studiesArthropod bites/papular urticariaConsider the differential diagnosis of arthropod/insect bites, which present with eosinophilic infiltration. Allergic/hypersensitivity reaction to insect bites, causing multiple intense pruritic nodules; possibility of residual hypo- or hyperchromic pigmentation on the skin, serious secondary infections, and scarring Differential diagnosis of chronic prurigo nodularis Guidelines recommend a complementary diagnostic work-up that may include laboratory testing and skin biopsy. European and American documents largely concur on the core investigations, whereas Japanese guidance is less detailed; Table 3 compares these approaches and underscores where recommendations converge or diverge [15, 80, 84]. In 2024, Spanish dermatologists proposed a diagnostic algorithm aligned with European criteria [27]. It accepts all lesion types (not only nodules) and uses history and examination to guide both differential diagnosis and etiologic categorization, integrating signs and symptoms, quality of life, productivity, patient-reported outcomes, and comorbidities. Final diagnoses fall into four categories: CPN associated with dermatologic disease, systemic/metabolic disease, psychiatric disease, or idiopathic CPN. This categorization is mainly intended to guide etiologic work-up and multidisciplinary management rather than to define distinct drug regimens for each subgroup [27]. Table 3Diagnostic approach by clinical guidelines in chronic prurigo nodularisAssessmentTestClinical evaluationHistory of prurigo nodularis• Duration of prurigo and associated pruritus (USA, EU)• Location and clinical condition of the skin at baseline and during the course (EU)• Severity of the disease, paying particular attention to the number and distribution of pruritic lesions• Associated diseases/drug intake (USA, EU, JPN)• Intensity of itching: NRS, IGA, PRO (USA, EU)Laboratory testsAll patients• Standard blood tests (USA, EU, Japan)• Erythrocyte sedimentation rate (EU)• Complete blood count (with differential) (USA, EU)• Ferritin, lactate dehydrogenase (EU)• Renal function tests (USA, EU)• Liver function tests (USA, EU)• HBV/HCV serology (USA, EU)• Thyroid function test (TSH) (USA, EU)• Fasting glucose or HbA1c (EU)If suspected:• Atopy: Total IgE (EU)• HIV: HIV serology (USA, EU)• Autoimmune skin diseases: indirect and direct immunofluorescence, ELISA BP-180/-230 (USA, EU)• Malignant neoplasm: additional targeted screening tests if there is a specific malignancy issue (USA)Additional tests• Biopsy: in cases of clinically atypical or refractory chronic prurigo, clinical signs of dermatological conditions requiring biopsy for diagnosis (USA, EU)HIV human immunodeficiency virus, ELISA enzyme-linked immunosorbent assay, EU European Union, HbA1c glycated hemoglobin, HBV hepatitis B virus, HCV hepatitis C virus, Ig immunoglobulin, IGA Investigator’s Global Assessment, JPN Japan, NRS numeric rating scale, PRO patient-reported outcome, TSH thyroid stimulating hormone Diagnostic approach by clinical guidelines in chronic prurigo nodularis History of prurigo nodularis • Duration of prurigo and associated pruritus (USA, EU) • Location and clinical condition of the skin at baseline and during the course (EU) • Severity of the disease, paying particular attention to the number and distribution of pruritic lesions • Associated diseases/drug intake (USA, EU, JPN) • Intensity of itching: NRS, IGA, PRO (USA, EU) All patients • Standard blood tests (USA, EU, Japan) • Erythrocyte sedimentation rate (EU) • Complete blood count (with differential) (USA, EU) • Ferritin, lactate dehydrogenase (EU) • Renal function tests (USA, EU) • Liver function tests (USA, EU) • HBV/HCV serology (USA, EU) • Thyroid function test (TSH) (USA, EU) • Fasting glucose or HbA1c (EU) If suspected: • Atopy: Total IgE (EU) • HIV: HIV serology (USA, EU) • Autoimmune skin diseases: indirect and direct immunofluorescence, ELISA BP-180/-230 (USA, EU) • Malignant neoplasm: additional targeted screening tests if there is a specific malignancy issue (USA) HIV human immunodeficiency virus, ELISA enzyme-linked immunosorbent assay, EU European Union, HbA1c glycated hemoglobin, HBV hepatitis B virus, HCV hepatitis C virus, Ig immunoglobulin, IGA Investigator’s Global Assessment, JPN Japan, NRS numeric rating scale, PRO patient-reported outcome, TSH thyroid stimulating hormone Disease Evaluation and Control Tools CPN severity and disease control can be assessed with several tools and scoring systems (Table 4), which collectively capture lesion activity, itch intensity, quality of life, sleep, and patient-perceived control [2, 3, 68, 73, 85–90]. One of the most widely used clinician-reported measures is the Investigator’s Global Assessment for PN (IGA-PN) [2, 85]. Others tools, such as the Prurigo Activity Score (PAS), provide greater granularity but are less practical for routine care, although a shorter version is available [2, 86]. Table 4Tools for the evaluation and control of chronic prurigo nodularis [2, 3, 68, 73, 85–90, 93]AssessmentToolClinician evaluation• Investigator’s Global Assessment Nodular Prurigo (IGA PN)• Prurigo activity score (PAS)Patient-reported outcomes• Pruritus (worst itch) numerical rating scale (WI-NRS)• Pruritus visual analog scale (VAS)• Pain numerical rating scale (NRS)• Prurigo Control Test (PCT)• ItchyQoLQuality of life and psychological assessment• Dermatology Life Quality Index (DLQI)• EuroQoL-5 dimensions (EQ-5D)• Hospital Anxiety and Depression Scale (HADS)Sleep assessment• Sleep numerical rating scale (NRS)• Epworth Sleepiness Scale (ESS)• PROMIS Sleep Disturbance Short Form 8a Tools for the evaluation and control of chronic prurigo nodularis [2, 3, 68, 73, 85–90, 93] • Investigator’s Global Assessment Nodular Prurigo (IGA PN) • Prurigo activity score (PAS) • Pruritus (worst itch) numerical rating scale (WI-NRS) • Pruritus visual analog scale (VAS) • Pain numerical rating scale (NRS) • Prurigo Control Test (PCT) • ItchyQoL • Dermatology Life Quality Index (DLQI) • EuroQoL-5 dimensions (EQ-5D) • Hospital Anxiety and Depression Scale (HADS) • Sleep numerical rating scale (NRS) • Epworth Sleepiness Scale (ESS) • PROMIS Sleep Disturbance Short Form 8a IGA-PN is popular because of its simplicity. It evaluates both disease activity (IGA-PN-A) and stage (IGA-PN-S) using a 5-point scale based on the number of active lesions (0, clear [no nodules] to 4, severe [> 100 dome-shaped palpable nodules]) [2, 85]. Quality of life is crucial in CPN. The most commonly used tool is the Dermatology Life Quality Index (DLQI), which is almost always impaired [88]. DLQI is a ten-item questionnaire assessing the impact of skin disease over the previous week; each item scores 0–3 (maximum 30), with higher scores indicating worse quality of life [88]. The Hospital Anxiety and Depression Scale (HADS) is also useful; it includes 14 items (7 for anxiety, 7 for depression), each subscale scored 0–21 (0–7, normal; 8–10, borderline; 11–21, abnormal) [89, 90]. To date, only DLQI has been formally validated in CPN, on the basis of phase III dupilumab trials in adults; therefore, other phenotypes and settings may be underrepresented [91]. Therefore, when possible, DLQI should be complemented with prurigo-specific tools such as the Prurigo Control Test (PCT) and/or ItchyQoL. One of the most recent instruments is the PCT, developed and validated to assess disease control from the patient’s perspective. It comprises five items covering the previous 2 weeks, each scored 0–4 (total 0–20; 0 = worst control, 20 = complete control) [92]. PCT is easy to use in routine practice and supports more focused, meaningful communication between patients and clinicians. The ItchyQoL is a pruritus-specific quality-of-life questionnaire that assesses symptoms, functional impairment, and emotional impact of chronic itch. It consists of 22 Likert-scale items scored from 1 (never) to 5 (all the time) and summed to generate domain and total scores, allowing sensitive monitoring of disease burden and treatment response [93]. Among sleep measures, the sleep NRS is widely used because of its simplicity: patients rate sleep quality over the previous 24 h on a 0–10 scale (10 = worst, 0 = best), although confusion about the direction of the scale can complicate interpretation. Treatment of Chronic Prurigo Nodularis The main goals of CPN treatment are to rapidly reduce pruritus, interrupt the itch–scratch cycle, heal lesions, and restore skin integrity. Contemporary consensus documents and treat-to-target proposals define meaningful response as clear or almost clear skin (IGA-PN 0/1) together with a clinically relevant reduction in itch intensity, usually at least 4 points on the WI-NRS or peak pruritus numeric rating scale (PP-NRS) [15, 27, 80, 94]. Because CPN burden is multidimensional, treatment assessment should also include quality of life, sleep, and patient-perceived control (Table 4), and management should incorporate evaluation of associated disease, psychiatric burden, and underlying triggers [3, 95]. For practical purposes, the therapeutic evidence can be divided into three tiers. High-quality evidence is currently limited to the phase III trials for dupilumab (PRIME/PRIME2) and nemolizumab (OLYMPIA1/OLYMPIA2), in which combined improvement in itch and lesion clearance represents a key response criterion [96, 97]. Intermediate-level evidence comes from phase II trials of agents such as JAK inhibitors. By contrast, most traditional off-label treatments summarized in Table 5 are supported only by small prospective cohorts, retrospective series, or case series. Table 5Off-label therapies for chronic prurigo nodularis supported mainly by low-level evidencePharmacological group/interventionNo. of studiesEffect on prurigoEffect on itch reductionLevel of evidence (according SIGN)*Topical corticosteroids2Significant improvement in lesionsModerate2+, 1+Topical calcineurin inhibitors3Improvement in inflammation and pruritusModerate–good1b, 2b, 2bTopical capsaicin3Significant reduction in nodulesGood2b, 2b, 3Phototherapy (ultraviolet B, UVB, psoralen photochemotherapy)10General improvementGood1+, 3, 3, 3, 3, 3, 3, 3, 3, 4Antihistamines3Limited effectLimited3, 3, 1bGabapentinoids6Decrease in pruritus and lesionsGood3, 3, 4, 4, 4Thalidomide/lenalidomide8Reduction in pruritusGood, but with adverse effects3, 3, 3, 4, 4, 4, 4, 4Opioid modulators (naltrexone, butorphanol)3Reduction in pruritusGood3, 3, 4NK1 antagonists (aprepitant, serlopitant)4Mixed efficacy, some with no effectMixt1b, 1b, 1+, 3Antidepressants (duloxetine, paroxetine, amitriptyline)4Improvement in itching and quality of lifeGood3, 4, 4, 2bMethotrexate (MTX)2Reduction in itching and lesionsGood3, 3Ciclosporin A (CSA)4Reduction in itching and lesionsGood3, 3, 3, 3Most therapies in this table are supported by case series, small uncontrolled cohorts, or retrospective series rather than by randomized phase III trials*The degree of evidence and recommendation was based on the SIGN methodology. Source: Scottish Intercollegiate Guidelines Network (SIGN). Forming guideline recommendations. In: SIGN 50: A guideline developers’ handbook: Edinburgh: SIGN; 2008 Off-label therapies for chronic prurigo nodularis supported mainly by low-level evidence Most therapies in this table are supported by case series, small uncontrolled cohorts, or retrospective series rather than by randomized phase III trials *The degree of evidence and recommendation was based on the SIGN methodology. Source: Scottish Intercollegiate Guidelines Network (SIGN). Forming guideline recommendations. In: SIGN 50: A guideline developers’ handbook: Edinburgh: SIGN; 2008 This distinction is clinically important. Off-label systemic agents may be useful in selected patients, especially when access to biologics is limited, but they are constrained by variable efficacy, monitoring burden, cumulative toxicity, and sparse long-term data. Even for targeted agents, important practical limitations remain, including long-term safety, cost, reimbursement restrictions, and unequal access across health systems. Table 6 summarizes the newer targeted and investigational therapies, and Fig. 2 proposes a pragmatic algorithm (only validated by the authors of this article) that integrates evidence level, safety considerations, and treatment availability. Table 6Targeted and investigational therapies for chronic prurigo nodularis, highlighting the current evidence hierarchyTreatment (references)Study name and designKey resultsSafety findingsLevel of evidence and grade of recommendation (SIGN)*Approved biologicsDupilumab (anti-IL-4α) [128]PRIME1Phase IIIRandomizedMulticentric151 patientsAt 12 weeks:• 44.0% with a reduction of ≥ 4 points in WI-NRS versus 15.8% placebo• 32.0% achieve IGA 0/1 versus 11.8% placeboAt 24 weeks:• 60.0% improvement of 4 points in WI-NRS versus 18.4% placebo• 48.0% with IGA 0/1 (“clear or almost clear skin”) versus 18.4% placebo• 38.7% with combined WI-NRS ≥ 4 points + IGA 0/1 versus 9.2% placebo• Well tolerated• Serious adverse events: 6.7% versus 8.0% (placebo)• Conjunctivitis: 2.7% versus 2.7% (placebo)• No Herpes viral infections• Nonherpetic skin infections: 2.7% versus 9.3% (placebo)• No treatment discontinuations due to adverse events2++ BPRIME2Phase IIIRandomizedMulticentric160 patientsAt 12 weeks:• 37.2% with a reduction of ≥ 4 points in WI-NRS versus 22.0% placebo• 25.6% achieve IGA 0/1 versus 12.2% placeboAt 24 weeks:• 57.7% improvement of 4 points in WI-NRS versus 19.5% placebo• 44.9% with IGA 0/1 (“clear or almost clear skin”) versus 15.9% placebo• 32.1% with combined WI-NRS ≥ 4 points + IGA 0/1 versus 8.5% placebo• Similar safety profile to other dupilumab indications• Serious adverse events: 2.6% versus 2.4% (placebo)• Conjunctivitis: 3.9% versus 0 (placebo)• Herpes viral infections: 5.2% versus 0 (placebo)• Nonherpetic skin infections: 5.2% versus 6.1% (placebo)• No treatment discontinuations due to adverse eventsNemolizumab (anti-IL-31) [97, 102]OLYMPIA1Phase IIIRandomizedMulticentric286 patientsAt 16 weeks:• Response to itching 58.4% versus 16.7% placebo• IGA 0/1 26.3% versus 7.3% placeboAt 24 weeks:• Response to itching 58.3% versus 20.4% placebo• IGA 0/1 30.5% versus 9.4% placeboDuring the treatment period, they had at least one adverse event: 71.7% for nemolizumab versus 65.3% for placebo; most events were mild to moderate in severity2++ BOLYMPIA2Phase IIIRandomizedMulticentric274 patientsAt 16 weeks:• 56.3% with clinically significant reduction in pruritus versus 20.9% placebo• 37.7% with IGA 0/1 versus 11% placeboThe most common individual adverse events were headache (6.6% versus 4.4%) and atopic dermatitis (5.5% versus 0%)2++ BSmall molecules: JAK inhibitors (off-label in CPN)Abrocitinib (JAK1 inhibitor) [103]Phase IIOpenTen patientsAt 12 weeks:• 80% reduction in pruritus (≥ 4 points on PP-NRS)• Decrease in IGA-PN from 3.6 to 2.5 (−30.6%)No relevant adverse effects were reported2+ CUpadacitinib (JAK1 inhibitor) [104]Prospective seriesTen patients• 100% with mild pruritus at 12 and 24 weeks• 80% achieve clinical remission at 24 weeks• Decrease in IGA-PN from 3.4 to 1.0Dyslipidemia in 10% of patients2+ CPovorcitinib (JAK1 inhibitor) [105]Phase II and extensionMulticentric146 patientsAt 16 weeks:• 54.1% achieve a reduction of ≥ 4 points in WI-NRS versus 8.1% placebo• 48.6% achieve IGA-PN 0/1 versus 5.4% placeboAt 40 weeks:• Sustained reduction in WI-NRS and PN-IGA at extensionMild adverse events (headache, fatigue, nasopharyngitis). Serious adverse events in 8.3% of patients2++ BEmerging biologics (investigational in CPN)Vixarelimab (anti-OSMRβ) [107]Phase IIaPlacebo controlled• 52.2% with improvement of ≥ 4 points in WI-NRS• 30.4% achieve IGA-PN 0/1 versus 7.7% placebo• Reduction in EVA pruritus by −54.4% versus −32.6% placeboMild adverse events (nasopharyngitis, headache, urticaria), without treatment interruptions2++ BWithin this table, dupilumab and nemolizumab are the only agents currently supported by phase III randomized data; the remaining agents are supported by phase II studies or early real-world experience*The degree of evidence and recommendation was based on the SIGN methodology. Source: Scottish Intercollegiate Guidelines Network. Forming guideline recommendations. In: SIGN 50: A guideline developers’ handbook: Edinburgh: SIGN; 2008 Targeted and investigational therapies for chronic prurigo nodularis, highlighting the current evidence hierarchy PRIME1 Phase III Randomized Multicentric 151 patients At 12 weeks: • 44.0% with a reduction of ≥ 4 points in WI-NRS versus 15.8% placebo • 32.0% achieve IGA 0/1 versus 11.8% placebo At 24 weeks: • 60.0% improvement of 4 points in WI-NRS versus 18.4% placebo • 48.0% with IGA 0/1 (“clear or almost clear skin”) versus 18.4% placebo • 38.7% with combined WI-NRS ≥ 4 points + IGA 0/1 versus 9.2% placebo • Well tolerated • Serious adverse events: 6.7% versus 8.0% (placebo) • Conjunctivitis: 2.7% versus 2.7% (placebo) • No Herpes viral infections • Nonherpetic skin infections: 2.7% versus 9.3% (placebo) • No treatment discontinuations due to adverse events PRIME2 Phase III Randomized Multicentric 160 patients At 12 weeks: • 37.2% with a reduction of ≥ 4 points in WI-NRS versus 22.0% placebo • 25.6% achieve IGA 0/1 versus 12.2% placebo At 24 weeks: • 57.7% improvement of 4 points in WI-NRS versus 19.5% placebo • 44.9% with IGA 0/1 (“clear or almost clear skin”) versus 15.9% placebo • 32.1% with combined WI-NRS ≥ 4 points + IGA 0/1 versus 8.5% placebo • Similar safety profile to other dupilumab indications • Serious adverse events: 2.6% versus 2.4% (placebo) • Conjunctivitis: 3.9% versus 0 (placebo) • Herpes viral infections: 5.2% versus 0 (placebo) • Nonherpetic skin infections: 5.2% versus 6.1% (placebo) • No treatment discontinuations due to adverse events OLYMPIA1 Phase III Randomized Multicentric 286 patients At 16 weeks: • Response to itching 58.4% versus 16.7% placebo • IGA 0/1 26.3% versus 7.3% placebo At 24 weeks: • Response to itching 58.3% versus 20.4% placebo • IGA 0/1 30.5% versus 9.4% placebo OLYMPIA2 Phase III Randomized Multicentric 274 patients At 16 weeks: • 56.3% with clinically significant reduction in pruritus versus 20.9% placebo • 37.7% with IGA 0/1 versus 11% placebo Phase II Open Ten patients At 12 weeks: • 80% reduction in pruritus (≥ 4 points on PP-NRS) • Decrease in IGA-PN from 3.6 to 2.5 (−30.6%) Prospective series Ten patients • 100% with mild pruritus at 12 and 24 weeks • 80% achieve clinical remission at 24 weeks • Decrease in IGA-PN from 3.4 to 1.0 Phase II and extension Multicentric 146 patients At 16 weeks: • 54.1% achieve a reduction of ≥ 4 points in WI-NRS versus 8.1% placebo • 48.6% achieve IGA-PN 0/1 versus 5.4% placebo At 40 weeks: • Sustained reduction in WI-NRS and PN-IGA at extension Phase IIa Placebo controlled • 52.2% with improvement of ≥ 4 points in WI-NRS • 30.4% achieve IGA-PN 0/1 versus 7.7% placebo • Reduction in EVA pruritus by −54.4% versus −32.6% placebo Within this table, dupilumab and nemolizumab are the only agents currently supported by phase III randomized data; the remaining agents are supported by phase II studies or early real-world experience *The degree of evidence and recommendation was based on the SIGN methodology. Source: Scottish Intercollegiate Guidelines Network. Forming guideline recommendations. In: SIGN 50: A guideline developers’ handbook: Edinburgh: SIGN; 2008 Pragmatic treatment algorithm for chronic prurigo nodularis. Evidence levels (SIGN methodology): 2++, high-quality systematic reviews/phase III RCTs with very low risk of bias; 2+, well-conducted case–control or cohort studies; 3, nonanalytic studies (case series); 4, expert opinion. *depending on patient characteristics, preferences and/or therapy accessibility. CPN chronic prurigo nodularis, DLQI Dermatology Life Quality Index, HADS Hospital Anxiety and Depression Scale, IGA-PN Investigator’s Global Assessment for PN, NB-UVB narrowband ultraviolet B, PCT Prurigo Control Test, PP-NRS pruritus peak numeric rating scale, Q2W/Q4W every 2/4 weeks, SD-NRS sleep disturbance numeric rating scale, SIGN Scottish Intercollegiate Guidelines Network, WI-NRS worst itch numeric rating scale In routine practice, gabapentinoids and other neural-directed agents are particularly relevant for patients with prominent neuropathic symptoms or sleep disturbance. However, the evidence base for gabapentin, pregabalin, antidepressants, phototherapy, cyclosporine, methotrexate, and thalidomide remains largely nonrandomized, and these options should be interpreted as empirically used therapies rather than as equivalently validated alternatives [98–101]. Dupilumab Dupilumab is a recombinant human IgG4 monoclonal antibody that blocks IL-4 signaling via the type I receptor (IL-4Rα/γc) and both IL-4 and IL-13 signaling via the type II receptor (IL-4Rα/IL-13Rα) [16]. PRIME and PRIME2 were randomized, double-blind, placebo-controlled phase III trials in patients with CPN inadequately controlled with topical therapy [96]. They enrolled 151 and 160 patients, respectively, randomized to placebo or dupilumab 300 mg every 2 weeks (600-mg loading dose) for 24 weeks plus 12 weeks of follow-up; low-to-moderate potency topical corticosteroids and topical calcineurin inhibitors were allowed [96]. Clinically meaningful itch improvement was significantly more frequent with dupilumab than with placebo (≥ 4-point WI-NRS reduction at week 24: 60% versus 18% in PRIME, and 58% versus 20% in PRIME2; both p < 0.0001), as was clear/almost clear skin (IGA-PN 0/1 at week 24: 48% versus 18% in PRIME, and 45% versus 16% in PRIME2; both p < 0.001) (Table 6). These benefits were consistent across baseline lesion severity and were similar in patients who were atopic and who were nonatopic. No patients discontinued dupilumab, and no new safety signals emerged; conjunctivitis rates were low and comparable to placebo in PRIME (2.7% in both arms) and only slightly higher with dupilumab in PRIME2 (3.9% versus 0%) [96]. Together with nemolizumab, dupilumab currently represents one of the two therapies with the strongest evidence base in CPN. Nemolizumab Nemolizumab is a humanized IgG2 monoclonal antibody that inhibits IL-31 signaling by selectively binding IL-31RA [17]. Its efficacy and safety were evaluated in the phase III randomized, double-blind, placebo-controlled OLYMPIA1 (24 weeks) and OLYMPIA2 (16 weeks) trials [97, 102]. OLYMPIA1 enrolled 286 patients and OLYMPIA2 274, who were randomized to nemolizumab (60-mg loading dose followed by 30 or 60 mg according to baseline weight) or placebo every 4 weeks. At week 16, a ≥ 4-point reduction in PP-NRS was achieved by 58.3% of patients receiving nemolizumab versus 16.7% receiving placebo in OLYMPIA1 and by 56.3% versus 20.98% in OLYMPIA2 (both p < 0.0001), with maintenance through week 24 in OLYMPIA1. IGA 0/1 rates were 26.3% versus 9.4% and 37.7% versus 11.0%, respectively (p < 0.0001) (Table 6). Most adverse events were mild or moderate; headache (6.6% versus 4.4%) and atopic dermatitis (5.5% versus 0%) were the most common events reported with nemolizumab [97, 102]. These phase III data place nemolizumab alongside dupilumab at the top of the current therapeutic evidence hierarchy in CPN. JAK Inhibitors Oral JAK1 inhibitors include abrocitinib [103], upadacitinib [104], and povorcitinib [105]. Among them, povorcitinib currently has the strongest CPN-specific dataset, based on a randomized phase II study. Patients were assigned to povorcitinib 15 mg (n = 36), 45 mg (n = 36), 75 mg (n = 37), or placebo (n = 37) for 16 weeks. A ≥ 4-point reduction in WI-NRS was achieved by 54.1% of patients receiving povorcitinib versus 8.1% receiving placebo, and 48.6% achieved IGA-PN 0/1 versus 5.4% with placebo. Benefit was maintained through the extension phase up to week 40 [105] (Table 6). Despite this promising signal, JAK inhibitors should currently be contextualized as investigational or selected-use options in CPN rather than as evidence-equivalent alternatives to dupilumab or nemolizumab. The available CPN-specific datasets remain early phase or derived from small real-world cohorts, and none have been specifically designed to assess long-term safety in this population. Importantly, the safety profile of JAK inhibitors warrants careful consideration in CPN, particularly given that the patient population is predominantly older (mean age 56–64 years) and carries a high comorbidity burden, including diabetes, hypertension, chronic kidney disease, and cardiovascular disease [106]. Accordingly, when JAK inhibitors are considered in CPN, an individualized risk–benefit assessment and close monitoring of safety parameters are essential. Emerging Therapies Several emerging biologics are being investigated for CPN. The anti-OSMRβ monoclonal antibody vixarelimab achieved rapid itch reduction and clear or almost clear skin in about one third of patients in a phase IIa prurigo nodularis study [107]. IL-4Rα–blocking antibodies such as rademikibart (CBP-201) have shown robust efficacy in phase II atopic dermatitis trials and are being developed for type 2-driven dermatoses [108, 109]. The OX40 antibody rocatinlimab and the anti-KIT antibody barzolvolimab are also in phase II development in type-2 inflammatory or mast cell–driven diseases, with promising antipruritic activity that may translate to CPN [110, 111]. At present, however, these agents remain investigational in CPN and should be interpreted as hypothesis-generating rather than practice-changing. Real-World Evidence Real-world evidence complements clinical trials by reflecting broader case-mix and routine-use safety [112], but in CPN, it remains dominated by uncontrolled small studies. Using the eligibility criteria summarized in Table 7, we identified 44 real-world studies: 9 case series, 19 prospective series, and 16 retrospective series. Most cohorts were small, heterogeneous, and at risk of selection and reporting bias, therefore, these data should be used mainly to support feasibility, tolerability, and external validity rather than to infer comparative efficacy. Table 7Eligibility criteria used for the real-world evidence subsection in chronic prurigo nodularis [101]Inclusion criteriaExclusion criteriaStudies involving patients of any age diagnosed with prurigo nodularisStudies with a population of patients without a diagnosis of prurigo nodularisStudies analyzing the results of different interventions used as topical and/or systemic treatment for prurigo nodularis, including the following:Studies that specifically analyze the effects of other interventions used to treat patients with prurigo nodularis will be excluded• Corticosteroids• Topical calcineurin inhibitors• UV phototherapy• Gabapentins• Antidepressants• Immunosuppressants• Mu opioid antagonists• Kappa opioid agonists/mu antagonists• Neurokinin-1 receptor antagonists• Monoclonal antibodies/biologics• Topical capsaicin• Antihistamines• Leukotriene inhibitors• Topical anesthetics• Topical steroids with occlusion using Unna boot• Antiretroviral therapy (seen in the context of HIV patients)• Sedatives• MontelukastStudies analyzing clinical efficacy through patient-reported response (VAS, NRS), subjective patient response (IGA), and quality of life (DLQI)Studies that analyze outcomes other than those included or that do not report clinical outcomesExperimental studies (clinical trials) and observational studies (prospective series, retrospective series, and case series)Nonprimary research methodologies, such as reviews, meta-analyses, commentaries, editorials, and letters, studies conducted on animals, or any study that did not provide sufficiently clear details about the methods used Eligibility criteria used for the real-world evidence subsection in chronic prurigo nodularis [101] • Corticosteroids • Topical calcineurin inhibitors • UV phototherapy • Gabapentins • Antidepressants • Immunosuppressants • Mu opioid antagonists • Kappa opioid agonists/mu antagonists • Neurokinin-1 receptor antagonists • Monoclonal antibodies/biologics • Topical capsaicin • Antihistamines • Leukotriene inhibitors • Topical anesthetics • Topical steroids with occlusion using Unna boot • Antiretroviral therapy (seen in the context of HIV patients) • Sedatives • Montelukast Earlier real-world literature focused mainly on thalidomide, methotrexate, cyclosporine, gabapentinoids, and other off-label therapies. Reported responses were sometimes substantial, but toxicity and discontinuation were non-negligible, particularly with thalidomide and methotrexate [101, 113, 114]. Since 2023, the most informative prospective cohorts have involved dupilumab, with consistent improvement in itch, lesion clearance, and quality of life, together with more limited but encouraging signals for abrocitinib and upadacitinib (Table 8) [103, 104, 115, 116]. Table 8Key recent prospective real-world series in chronic prurigo nodularisDupilumab (n = 73) [116]Abrocitinib (n = 25) [103]Upadacitinib (n = 10) [104]Percentage of patients with a reduction in the NRS score for itching ≥ 4 points84.9% week 1280% week 12100% week 4PP-NRS score (basal score → end score)7.9 → 5.2 week 2→ 2.1 week 12→ 1.9 week 169.2 → 2.0 week 128.1 → 1.5 week 4→ 0.8 week 12→ 0.8 week 24IGA score (basal score → end score)3.5 → 3.3 week 2→ 1.9 week 12→ 1.6 week 163.6 → 2.5 week 123.4 → 2.3 week 4→ 1.4 week 12→ 1.0 week 24DLQI score (basal score → end score)16.6 → 12.5 week 2→ 7.21 week 12→ 6.5 week 1619.0 → 8.9 week 1217.8 → 3.4 week 4→ 1.8 week 12→ 0.6 week 24Safety• Dry eyes (n = 1; 1.4%)• No serious adverse events were reported• No treatment discontinuations or withdrawals• Acneiform eruption (n = 2; 10%)• No serious adverse events were reported• No treatment discontinuations or withdrawals• Dyslipidemia (n = 1; 10%)• No serious adverse events were reported• No treatment discontinuations or withdrawalsDLQI Dermatology Life Quality Index, IGA Investigator’s Global Assessment, PP-NRS pruritus peak numeric rating scale, NRS numerical rating scale Key recent prospective real-world series in chronic prurigo nodularis 7.9 → 5.2 week 2 → 2.1 week 12 → 1.9 week 16 8.1 → 1.5 week 4 → 0.8 week 12 → 0.8 week 24 3.5 → 3.3 week 2 → 1.9 week 12 → 1.6 week 16 3.4 → 2.3 week 4 → 1.4 week 12 → 1.0 week 24 16.6 → 12.5 week 2 → 7.21 week 12 → 6.5 week 16 17.8 → 3.4 week 4 → 1.8 week 12 → 0.6 week 24 • Dry eyes (n = 1; 1.4%) • No serious adverse events were reported • No treatment discontinuations or withdrawals • Acneiform eruption (n = 2; 10%) • No serious adverse events were reported • No treatment discontinuations or withdrawals • Dyslipidemia (n = 1; 10%) • No serious adverse events were reported • No treatment discontinuations or withdrawals DLQI Dermatology Life Quality Index, IGA Investigator’s Global Assessment, PP-NRS pruritus peak numeric rating scale, NRS numerical rating scale Recent retrospective studies largely confirm the rapid antipruritic and lesion-level benefit of dupilumab observed in clinical trials [117–122]. Limited real-world experience with nemolizumab also suggests meaningful improvement, but cutaneous adverse events have been reported and require monitoring [123, 124]. Overall, the main value of real-world evidence at present is to confirm the effectiveness of the approved biologics in more diverse patients and to highlight safety and access issues that are less visible in randomized trials. Current Guidelines for the Treatment of Chronic Prurigo Nodularis The International Forum for the Study of Itch (IFSI) guideline (2020) and the European and US expert consensuses propose stepwise approaches to CPN diagnosis and management, but they are consensus-based, nonpersonalized, and largely pre-phase III with respect to dupilumab and nemolizumab; consequently, they provide limited patient-tailored therapeutic guidance [15, 80, 84, 101, 125]. These documents consistently begin with trigger control and topical anti-inflammatory therapy and then escalate to phototherapy or systemic agents, but they differ in how explicitly they separate neural-directed from immune-directed options. One consensus proposes an algorithm that starts with high-potency topical corticosteroids for flares, calcineurin inhibitors for maintenance, and capsaicin for localized disease, with phototherapy or systemic agents added when response is inadequate [125]. The Japanese consensus is broadly similar but recommends reevaluating the diagnosis and considering biopsy if all treatment lines fail [84]. Notably, most guidelines were developed before the availability of phase III biologic data and therefore rely heavily on off-label treatments supported by lower-quality evidence. This helps explain why frequently used therapies such as antihistamines continue to appear prominently despite the limited mechanistic rationale for histamine blockade in CPN [24, 80, 126]. The recent SWITCH algorithm moves closer to a treat-to-target model by linking therapeutic decisions to pruritus, lesion count, quality of life, and sleep [94]. Building on that concept, Fig. 2 provides a simplified pragmatic algorithm that prioritizes high-level evidence when available, reserves off-label or investigational agents for selected circumstances, and emphasizes repeated reassessment every 3–6 months. Unmet Needs in Chronic Prurigo Nodularis Management Despite recent progress, the management of CPN is currently facing urgent unmet needs, which highlight the necessity for clearer therapeutic strategies: First, harmonized terminology, diagnostic criteria, and therapeutic guidance are still needed across regions; current recommendations remain largely consensus-based and leave substantial room for variability in practice [127]. First, harmonized terminology, diagnostic criteria, and therapeutic guidance are still needed across regions; current recommendations remain largely consensus-based and leave substantial room for variability in practice [127]. Second, treatment sequencing and combination strategies remain poorly defined. Clinicians still lack evidence-based guidance on when to escalate, switch, taper, or combine systemic and topical therapies. Second, treatment sequencing and combination strategies remain poorly defined. Clinicians still lack evidence-based guidance on when to escalate, switch, taper, or combine systemic and topical therapies. Third, the neurogenic and fibrotic components of CPN remain undertargeted. Although these pathways are biologically central, therapies specifically directed at neural sensitization or fibrosis are still limited [127]. Third, the neurogenic and fibrotic components of CPN remain undertargeted. Although these pathways are biologically central, therapies specifically directed at neural sensitization or fibrosis are still limited [127]. Fourth, long-term data and guidance for special populations are scarce, including children, older adults, pregnant patients, and individuals with major cardiometabolic or psychiatric comorbidity. Fourth, long-term data and guidance for special populations are scarce, including children, older adults, pregnant patients, and individuals with major cardiometabolic or psychiatric comorbidity. Finally, access remains a major unmet need: even when biologics are available, cost, reimbursement restrictions, and health-system inequities may delay the use of the agents with the strongest evidence. Finally, access remains a major unmet need: even when biologics are available, cost, reimbursement restrictions, and health-system inequities may delay the use of the agents with the strongest evidence. These gaps underscore the complexity of CPN and the need for more practical and personalized guidance. Future research should prioritize biomarker-informed phenotyping, pragmatic comparative trials, long-term safety data, and digital endpoints to better define CPN subtypes and treatment response. Acknowledgments Medical Writing/Editorial Assistance The authors thank Fernando Sánchez Barbero, PhD on behalf of Springer Health+ for his help in preparing this manuscript. Medical writing was funded by Sanofi. Author Contributions Esther Serra-Baldrich: conceptualization, investigation, writing original draft, review and editing successive drafts, and final approval of the manuscript. Ángeles Flórez: conceptualization, investigation, writing original draft, review and editing successive drafts, and final approval of the manuscript. Marc Julià Manresa: conceptualization, investigation, writing original draft, review and editing successive drafts, and final approval of the manuscript. Francisco Javier Ortiz de Frutos: conceptualization, investigation, writing original draft, review and editing successive drafts, and final approval of the manuscript. José-Juan Pereyra-Rodriguez: conceptualization, investigation, writing original draft, review and editing successive drafts, and final approval of the manuscript. Bibiana Pérez: conceptualization, investigation, writing original draft, review and editing successive drafts, and final approval of the manuscript. Ignasi Figueras: conceptualization, investigation, writing original draft, review and editing successive drafts, and final approval of the manuscript. Funding Sanofi provided funding exclusively for a medical writer to collect the information and for the rapid service fee, without any involvement in the writing process or in the authors’ opinions. Data Availability Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study. Declarations Conflict of interest Ignasi Figueras has received honoraria or support for training activities, has acted as a speaker or consultant, or has participated in clinical trials from Abbvie, Almirall, Amgen, Apogee Therapeutics, Celldex Therapeutics, Celgene, Galderma, Incyte, Johnson & Johnson, Leo-Pharma, Lilly, Pfizer, Sanofi, Regeneron, Zuelling Pharma, and DKSH. Ángeles Flórez has received honoraria or support for training activities, has acted as a speaker or consultant, or has participated in clinical trials from Abbvie, Almirall, Amgen, Apogee Therapeutics, Celldex Therapeutics, Celgene, Galderma, Incyte, Janssen, Johnson & Johnson, Leo-Pharma, Lilly, Pfizer, Roche Farma, and Sanofi. Marc Julià Manresa has received honoraria or support for training activities, has acted as a speaker or consultant, or has participated in clinical trials from Abbvie, Almirall, Leo-Pharma, Lilly, Pfizer, and Sanofi. Francisco Javier Ortiz de Frutos has received honoraria for consultant or training activities from Novartis, Astellas, BDF, Uriach, Sanofi, GSK, Pfizer, Abbvie, Lilly, MSD, Leo and Almirall, or has participated in clinical trials from Astellas, Novartis, Bayer, Sanofi, Leo, Lilly, Pfizer, Abbvie; or has received grants for attendance of congress from Isdin, Menarini, Astellas, Novartis, MSD, Sanofi, Leti, and Leo. José Juan Pereyra has received honoraria for research from Novartis, AbbVie, and Sanofi; and for lecturing and other financial benefits from AbbVie, Almirall, Galderma, Janssen, Gebro-Pharma, Leo-Pharma, Novartis, Lilly, Novartis, Pfizer, Sanofi, and UCB. Bibiana Pérez has received honoraria or support for training activities, has acted as a speaker or consultant, or has participated in clinical trials from Abbvie, Almirall, Amgen, Galderma, Incyte, Leo-Pharma, Lilly, Pfizer, and Sanofi. Esther Serra-Baldrich has received honoraria or support for training activities, has acted as a speaker or consultant, or has participated in clinical trials from Abbvie, Almirall, Amgen, Apogee Therapeutics, Celldex Therapeutics, Galderma, Incyte, Leo-Pharma, Lilly, Pfizer, Roche Farma, and Sanofi. Ethical Approval This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.